Activation of the muscarinic M 1 receptor is a promising approach to improve cognitive 17 deficits associated with cholinergic dysfunction in Alzheimer's disease, dementia with Lewy 18 bodies, and schizophrenia. TAK-071 is an M 1 -selective positive allosteric modulator that improves 19 cognitive deficits induced by scopolamine, a non-selective muscarinic receptor antagonist, with 20 reduced side effects on gastrointestinal function in rats. In this study, we explored changes in 21 quantitative electroencephalography (qEEG) power bands, with or without scopolamine challenge, 22 as a non-invasive translational biomarker for the effect of TAK-071 in cynomolgus monkeys.
Introduction 37
Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) are progressive 7 110 with the recommendations of the Weatherall report on the use of non-human primates in research. 111 Male cynomolgus monkeys (Macaca fascicularis) were purchased from Hamri Company Limited 112 (Ibaraki, Japan). The monkeys were individually housed and maintained in accordance with the 113 guidelines approved by AAALAC. They were given water ad libitum and fed once daily with a 114 complete, nutritionally balanced diet enriched with fruits and gummy candies. All monkeys, 115 housed and handled in strict accordance with the guidelines for good animal practice under the 116 supervision of veterinarians, received environmental enrichment and were monitored for 117 evidence of disease and changes in attitude, appetite, or behavior suggestive of illness. In 118 addition, every effort was made to alleviate animal discomfort and pain by routine use of 119 appropriate anesthetic and analgesic agents. Implant surgery was carried out at Hamri Company Limited (Ibaraki, Japan). Briefly, 123 under isoflurane anesthesia (1-5%, Pfizer Japan Inc., Tokyo, Japan), male cynomolgus 124 monkeys (3-5 years old, Hamri Co., Ltd., Ibaraki, Japan) were surgically implanted with 125 radio-telemetry transmitters (TL10M3-D70-EEE, Data Sciences International Inc., St. Paul, 126 MN). EEG leads were stereotactically positioned in the parietal area and secured to the cranium 127 with stainless-steel screws in contact with the dura. Unilateral electrooculography (EOG) leads 128 were positioned at the superior orbital margin of one eye and secured with stainless-steel screws. continuously throughout the experiment. The recordings were performed between 9 a.m. and 4 155 p.m..
Chemical treatment
136 TAK-071, 137 4-fluoro-2-[(3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl]-5-methyl-6-[4-(1H-pyrazol-1-yl)benzyl]-2 138 ,3-dihydro-1H-isoindol-1-one,
156
EEG data were analyzed off-line using SleepSign (KISSEI COMTEC Co., Ltd., Nagano, 157 Japan). Digitized EEG signals were high-pass filtered with a 0.75-Hz filter. Spectral power densities 158 for each frequency band were calculated by fast Fourier transform in consecutive 10-s epochs.
159
Epochs containing abnormal EEG, defined by excessive amplitude (> 500 μV), were omitted from 160 data analysis. For analysis of temporal changes in a specific spectral band (1-4 Hz for delta, 4-8 Hz 161 for theta, 8-12 Hz for alpha, 12-30 Hz for beta, 30-80 Hz for gamma), the EEG power of each 162 spectral band was calculated every 15 min. For each animal, the qEEG spectral analyses were 163 performed from 30 to 240 min after treatment because oral and subcutaneous administration of 164 drugs to monkeys can affect the qEEG power spectra. Data obtained in the post-drug period were 165 normalized with those obtained in the baseline period and were calculated as the area under the 166 curve (AUC) between 30 and 210 min after drug administration for quantitative analyses. In clinical trials, multiple lines of evidence have suggested that scopolamine treatment 178 induces qEEG power spectral changes, particularly increases in theta and delta power bands and 179 decrease in alpha power band [27, 30, 31] . Initially, we examined the effects of scopolamine in 180 qEEG power spectra in cynomolgus monkeys. To evaluate dose-dependency, scopolamine was 181 subcutaneously administered at 25, 50, or 100 μg/kg to monkeys. Indeed, scopolamine increased 182 alpha, theta, and delta power bands in a dose-dependent manner ( Fig 1A-C) . These effects in all 183 power bands persisted for 240 min after treatment, and peak increases were observed between 60 184 and 90 min after treatment. The time-dependent changes of each qEEG spectrum during 185 scopolamine treatment relatively corresponded to its PK profile (S1 Fig and S1 Table) . Alpha, theta, administered to monkeys. The dose of donepezil for this study was determined based on the 207 previous report, which showed that oral treatment of donepezil at 1-3 mg/kg significantly 208 attenuated the scopolamine-induced cognitive deficits in monkeys [33] . The increases in alpha and 209 theta power bands induced by scopolamine treatment tended to be attenuated by donepezil (Fig 2A   210 and B). Furthermore, in accordance with the previous report in rats [28] , donepezil significantly 211 suppressed the scopolamine-induced increase in the delta power band ( Fig 2C) . These effects were 212 observed between 60 and 240 min after drug treatment (Fig 2A-C) . 213 Furthermore, we examined the effects of donepezil on qEEG power spectra. Oral treatment 214 of donepezil at 0.3 mg/kg alone increased alpha power band, whereas the dose-dependency was not 215 observed (S3 Fig A) . Donepezil (0.3 and 3 mg/kg) did not affect theta and delta power bands (S3 Fig 3A-C) . The scopolamine-induced increases in alpha, theta, and delta power bands were 238 continuously inhibited between 60 and 240 min after treatment, although these effects were not 239 statistically significant (Fig 3A-C) . Thus, M 1 R and/or M 4 R antagonism may contribute to the qEEG 240 power spectral changes caused by scopolamine treatment. whether TAK-071 affected the qEEG power spectral changes caused by scopolamine treatment. We 256 previously reported that TAK-071 at 0.3 mg/kg significantly ameliorated the scopolamine-induced 257 cognitive deficits, with a maximum plasma comcentration of 232 ng/mL in rats [11] . Based on the 258 PK profile of TAK-071 in monkeys (S2 Table) , the doses of TAK-071 were selected at 0.3-3 mg/kg 259 to cover the effective plasma concentration in rats. Monkeys were simultaneously administered 260 TAK-071 (0.3-3 mg/kg, p.o.) and scopolamine (25 μg/kg, s.c.). TAK-071 at 1 mg/kg significantly 261 reduced the scopolamine-induced increase in alpha power band, whereas at 3 mg/kg, TAK-071 significantly suppressed the increases in both alpha and theta power bands (P ≤ 0.05, Fig 4A and 263 B). Although there was no significant effect on delta power band, a decreasing trend was observed 264 when TAK-071 was administered at 1 and 3 mg/kg ( Fig 4C) . Remarkably, these effects lasted 265 between 90 and 240 min after drug administration (Fig 4A-C) .
266
In addition to the scopolamine challenge paradigm, the effects of TAK-071 alone on qEEG 267 power spectra were evaluated. Oral treatment of TAK-071 significantly decreased alpha and theta 268 power bands at 1 and 3 mg/kg and at 1 mg/kg, respectively (P ≤ 0.05, S4 Fig A and B) . In contrast,
269
TAK-071 (0.3-3 mg/kg) did not change delta power band (S4 Fig C) . 
286
Typical EEG abnormalities in patients with AD and DLB are associated with a decrease in 287 alpha power band, which leads to increases in theta and delta power activities [16] [17] [18] [19] . Several 288 reports have demonstrated that scopolamine caused changes in qEEG power spectra in healthy 289 subjects [27, 30, 31] , which in part corresponded to those in patients with AD and DLB. Therefore, 290 it is considered that the scopolamine model could reflect some aspects of the cholinergic deficit in 291 AD and DLB in both PD and cognition. In addition to the findings from clinical studies, a 292 scopolamine-induced increase in delta power band was also detected in freely moving rats [28, 29] .
293
In line with the findings of clinical and preclinical studies, in this study we showed that 294 scopolamine caused qEEG spectral changes in a dose-dependent manner, in particular, increases in 295 theta and delta power bands in monkeys (Fig 1) . We selected cynomolgus monkeys, not rodents, 296 because monkey brains more closely resemble human brains than do rodents. Furthermore, 297 monkeys are diurnal animals, and we considered it essential that the studies be performed under the 298 same conditions as clinical studies, i.e., during daytime.
299
Among the scopolamine-induced changes in qEEG power spectra, the increases in theta and 17 300 delta power bands in monkeys were similar to those reported in humans. Therefore, at least the 301 effects of cholinergic agents in these power bands could be useful as translational biomarkers in the 302 scopolamine challenge paradigm.
303
On the other hand, the increase in alpha power band in monkeys ( Fig 1A) was opposite to 304 the results in humans [27, 31] . It is known that alpha activity of the EEG power spectra is enhanced treatment was relatively consistent with its PK profile (S1 Fig and S1 Table) . Therefore, the current 314 study suggests that the PK/PD relationship of scopolamine was detected in monkeys.
315
In line with the previous studies that reported significant suppression of the 316 scopolamine-induced increase in delta power band by AChE inhibitors in rats [28, 29] , this study 317 also demonstrated that donepezil counteracted the scopolamine-induced increases in alpha, theta, 318 and delta power bands (Fig 2) . Furthermore, both xanomeline and TAK-071 showed the potential to 18 319 inhibit the scopolamine-induced qEEG spectral changes (Figs 3 and 4) . Taken together, these 320 results suggest that the scopolamine-induced increases in alpha, theta, and delta power bands were 321 suppressed partly through M 1 R activation in monkeys. In addition to the scopolamine challenge 322 paradigm, we examined the effects of donepezil (0.3 and 3 mg/kg) and TAK-071 (0.3-3 mg/kg) on 323 qEEG power spectra, and found that TAK-071 treatment alone slightly decreased alpha and theta 324 power bands, whereas donepezil treatment alone did not decrease the qEEG power spectra (S3 and 325 S4 Figs). Similar results were reported by Uslaner, where MK-7622, a selective M 1 PAM, showed 326 reductions of alpha and theta power bands [42] . The discrepancy between TAK-071 and donepezil 327 may be explained by selective M 1 R signal transduction. In our previous study, TAK-071 was 328 demonstrated to be a highly selective M 1 PAM [11] . In contrast, donepezil indirectly and 329 non-selectively activates both nicotinic and muscarinic receptors by increasing ACh levels in the 330 synaptic clefts, which might lead to a masking effect on the decrease in qEEG power spectra 331 through M 1 R activation. In fact, another AChE inhibitor, galantamine, did not change theta power 332 band in healthy young volunteers [43] .
333
In this study, we did not examine the direct association between qEEG spectral changes and 334 cognitive deficits by scopolamine treatment in monkeys. Thus, it would be difficult to predict the 335 effective dose of TAK-071 for cognitive improvements from the qEEG results in monkeys because 336 the relationship between the effective doses at which cognitive improvement is observed and the 337 induction of qEEG spectral changes remains unclear. However, both oral administration of 3 mg/kg 19 338 donepezil and intramuscular administration of 0.1 mg/kg xanomeline improved 339 scopolamine-induced cognitive deficits in monkeys [33, 44] . Furthermore, it is considered that 340 qEEG abnormalities are correlated with the severity of cognitive impairment in AD and DLB 341 [20] [21] [22] . While no direct comparisons were made in this study, inferences might be drawn about the 342 effects on qEEG power spectra and cognition in monkeys. Hence, scopolamine-induced qEEG 343 spectral changes may also be useful as a translational biomarker in humans for evaluation of 344 procognitive effects of TAK-071. 
